Elutia Regains Compliance with Nasdaq Listing Requirements
SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq:ELUT) today announced that it has regained compliance with Nasdaq’s market value of listed securities requirement and majority independent board requirement. As a result, the Company now satisfies all applicable requirements for continued listing with Nasdaq, and the Company’s Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”
Related news for (ELUT)
- Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
- Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
- Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
- Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
- Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice